Podcasts about Eras

James Clear is the author of Atomic Habits, a global bestseller that has shaped how millions of people think about habits, consistency, and long-term change. In this conversation, James explains how habits shape identity, why progress often stays invisible before it compounds, and how to design your environment so good behavior becomes the default. You will learn how to stay consistent when motivation fades, stop quitting too early, and build habits that work across different seasons of life. ----- Approximate Timestamps: (00:00) Introduction (00:56) The Role of Identity in Habit Formation (03:38) Lack of Patience Changes the Outcome (07:20) Seeing Invisible Progress (09:58) Why Do We Change What's Working? (13:46) Creating Conditions for Success (17:44) Finding the Confidence to Start (23:55) Playing to Win vs. Playing Not to Lose (26:29) Internal Sayings to Live By (30:36) Reputation (34:32) Positioning in Business and Life (44:36) Investment Philosophy (47:18) Turning Reading Habits into Action (50:31) Taking Notes While Reading... (52:36) ...And Then What? (56:06) Maintaining Focus on What You Want (58:01) Lessons on Filtering Opportunities (01:06:06) Longevity of Content (01:07:21) Sequencing Through the Eras of Your Life (01:11:22) What is a Habit? (01:13:03) Is a Habit Working For You or Against You? (01:15:20) Evaluation Framework for Habits (01:18:32) Building or Replacing a Habit (01:22:19) Social Media Detox (01:25:34) The Most Important Upstream Habits to Create (01:29:58) Relationship Check-In (01:30:57) Thoughts on Popular Habits (01:37:31) Become Stronger Than Your Feelings (01:42:59) When Should You Deep Dive into an Idea (01:48:12) Complexity vs. Simplicity (01:54:40) Consistency vs. Intensity (02:01:11) Learning New Subjects as an Adult (02:06:40) Prioritization (02:11:53) What is Success For You? ----- Upgrade: Get a hand edited transcripts and ad free experiences along with my thoughts and reflections at the end of every conversation. Learn more @ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠fs.blog/membership ------ Newsletter: The Brain Food newsletter delivers actionable insights and thoughtful ideas every Sunday. It takes 5 minutes to read, and it's completely free. Learn more and sign up at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠fs.blog/newsletter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ------ Follow Shane Parrish:X: ⁠⁠⁠⁠⁠⁠https://x.com/shaneparrish⁠ Insta: ⁠https://www.instagram.com/farnamstreet/⁠ LinkedIn: ⁠https://www.linkedin.com/in/shane-parrish-050a2183/⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we're deep diving the first movie of the Twilight Saga. Join us as we relive the glittery angst, questionable life choices, and epic baseball scene that made this series iconic - for better or worse. It's the perfect way to remember the magic (or madness) of Twilight without actually rewatching the movies.Relevant links: Our full show notes are at knoxandjamie.com/640Happy Holidays from The PMG! We hope you enjoy this first episode of The Twilight Collection. To own all five episodes, head to knoxandjamie.com/twilight and use code JACKSONVILLE to save! (This one-time use code is valid only on the Twilight Collection)The Movie: Watch It | Rotten Tomatoes | Read It | Goodreads | The SoundtrackIMDbs: Kristen Stewart | Robert Pattinson | Catherine Hartwicke | Carter Burwell | Cam Gigandet | Taylor Lautner (see also: podcast | Eras appearance)More Deep Dives: The Harry Potter Collection | Faith Adjacent Marvel Bundles | Narnia Sacred Cinema & Books Books Mentioned: Midnight Sun by Stephenie Meyer | Fifty Shades of Grey by E.L. James | Other Stephenie Meyer book (see also: movie adaptation)Must Haves: Edward's Peacoat | Cullen's HouseDrive-By Mentions: Exclusive Covers in Entertainment Weekly | Percy Jackson | David Harper Santa Movie | Zoolander | Bonus segment: Join us on Patreon to listen ad-free and get exclusive content, including more Cinema Sidepieces like: Goonies, Armageddon, Cruel Intentions and Sinners.Episode sponsors: Soul CBD (code: POPCAST) | Royal Match (Google Play & App Store) Hosted on Acast. See acast.com/privacy for more information.

And just like that, Taylor Swift's 'The End Of An Era' docuseries has come to a close. We are so sad it's over but we absolutely loved the way it ended. The focus of family, story of Marjorie, and recap of the Toronto shows in episode 5 had us tearing up! Plus we got to see the idea for THE dive come to life! And at last, in episode 6 we got to see so much of Gracie and Taylor, revisiting special 22 hat moments and the why behind it, a recap of the final shows in Vancouver, and Taylor watching the Chiefs game on the last day of tour while getting ready had us laughing, smiling, and in tears. The end of an era and the end of 2025! We are so excited for another year of the podcast in 2026. Hit that subscribe button so you don't miss any future episodes.SPONSORS:DIME Beauty (TYPICALTUESDAYNIGHT for 20% off): https://go.shopmy.us/p-22911520Walli Cases (TTN for 10% off) https://wallicases.com/?rstr=ttnTaylor Swift Podcast || Best Taylor Swift Podcast || The End of an Era || Taylor Swift Docuseries || Taylor Swift and Travis Kelce || Taylor and TravisSend us a textSupport the showFollow along to hear a new Taylor Swift related episode every single Tuesday.Watch our episodes on YouTube!Follow Us On Social Media:Typical Tuesday Night Podcast @typicaltuesdaynight.podcastKarli @everyday_ellisJess @jess.taitJoin our Patreon for bonus episodes and exclusive Taylor Swift group chat!Shop Our Merch!Feel free to contact us at typicaltuesdaynightpodcast@gmail.com

In this episode, JGME Executive Editor, Dr. Nicole Deiorio, speaks with Dr. Rachel Wolfson and Dr. Jeffery Riddell about their article, "From Volume to Value: Curbing the Arms Race in Medical Student Research." They discuss new changes to the ERAS application, the future of medical student research, and a call to action for program directors and the NRMP.  

I'm back! We've moved to The Netherlands and are getting settled in, and I'm ready to start recording episodes again!All the struggles that came with making that huge move had me thinking about how we can have a tendency to be in elemental phases, and how that also correlates to a main "default" phase for each stage of life, like Maiden, Mother, and Crone (or child, adult, and older). What if the Crone/Older phase isn't about time, but about using the elements? Let's talk about that!

In this episode, Adam and Dan  discuss their holiday preparations, share personal anecdotes, and dive deep into band logistics for smoother operations. The main thrust of the episode is a detailed look at Taylor Swift's leadership approach during her ERAS tour, including her meticulous involvement in all aspects of the production. Adam and Dan relate these insights back to their experiences in managing their own bands. Tune in for a mix of  stories, practical advice, and a fascinating glimpse into one of the biggest tours in music history.MaestroDMX (10% off discount link): https://maestrodmx.com/discount/DISCOUNT4CBC?redirect=%2Fproducts%2FmaestrodmxBlank Contracts & Riders: https://www.coverbandconfidential.com/store/performance-contractsBacking Track Resources: https://www.coverbandconfidential.com/store/backing-track-resourcesThank you so much for tuning in!  If you want to help be sure to like, subscribe and share with your friends!  Linktree: linktr.ee/adampatrickjohnson                linktr.ee/coverbandconfidentialFollow us on Instagram!@coverbandconfidential@adampatrickjohnson@danraymusicianIf you have any questions please email at:Coverbandconfidential@gmail.comConsider supporting us on Patreon! www.patreon.com/coverbandconfidentialOr buy us a cup of coffee!paypal.me/cbconfidentialAnd for more info check out www.coverbandconfidential.comGear Used in this Video (Affiliate):Sony ZV-E10 Mirrorless Camera: https://amzn.to/3DBqtOyElgato Prompter: https://amzn.to/3X3IAq8 Shure SM7B: https://amzn.to/4dDCJx0 Elgato Stream Deck XL: https://amzn.to/3gKjhqiMagic Arm Camera Friction Mount: https://amzn.to/3SK5yNk

This week on Page 7, Jackie and MJ are reunited with Holden to talk about how that dirty fucking child from Christmas Shoes should learn to BATHE to stop illin' his mom, the tragedy of Rob and Michele Reiner, and it's time to dig into some feminine rage because Martha Stewart eats a bagel real weird. Dick Van Dyke made it 100 against his own wishes, happy bday! Holden's wearin' his cardigan as we dive into some quick Swiftie talk and share disappointment about her SILENCE, SKIMS got themselves an Ozempic Santa because of course they did, David Letterman keeps gettin' confused for Dick Van Dyke, so let that speak for his skin care routine, and Holden's enjoyin' the new Eras tour doc thing! Next we got our list and we're checkin' it twice 'cause it's a list full of NATIONAL LAMPOONS CHRISTMAS VACATION FAAAAAAAAACTS!!!!! Followed by Blindz Timez, with a Jackie's Snackies @ 1:15:30.608 and an MJ's Minute Munchies @ 1:23:09.000, until 1:25:40! All that and more on this week's Page 7! Want even more Page 7? Support us on Patreon! Patreon.com/Page7Podcast Subscribe to SiriusXM Podcasts+ to listen to new episodes of Page 7 ad-free.Start a free trial now on Apple Podcasts or by visiting siriusxm.com/podcastsplus. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Taylor Swift's The End of an Era documentary is already breaking Disney records, so we review the first two episodes. Is it pure hagiography or genuinely insightful? Also on the show: why Bonnie Blue wrote a Spectator op-ed backing Nigel Farage, George Clooney's new marital rule, and the surprising subculture that's helped make Zootopia 2 box office gold. Plus a review of Alchemised, the incredible fanfic inspired by Harry Potter and the Housemaid's Tale that netted a seven-figure film deal. Enjoy hunnies and remember next week's ep is dropping on Tuesday!Enjoy and please do let us know what you think of the ep, share your recs and just generally get in touch on IG ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@straightuppod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or email at ⁠⁠hello@straightuppodcast.co.uk⁠. We LOVE hearing from you!Follow us on TikTok @straightuppodRecs/ reviews Backstage Beauty SalonAlchemised, SenLinYuThe fanfiction written on a notes app that's become a bestseller – with a seven-figure film deal, GuardianMargaret Atwood on Desert Island Discs, BBC Sounds The MaddAddam Trilogy, Margaret AtwoodCece, Emmelie PropheteGrace Beverley: the Oxford student with a £70m wellness brand, The Times I stand with Nigel Farage, Spectator Zootopia 2, in cinemas nowWake Up Dead Man: A Knives Out Mystery, Netflix Taylor Swift: The End of an Era, Disney. Hosted on Acast. See acast.com/privacy for more information.

"Khi nói đến kinh doanh, lợi nhuận là yếu tố thường được các doanh nghiệp đặt lên hàng đầu. Nhưng với tôi, giá trị thật - sản phẩm thật luôn là giá trị cốt lõi trong hoạt động kinh doanh của một doanh nghiệp bất động sản…”.Đó chính là chia sẻ của bà Bà Nguyễn Hương, Tổng Giám đốc Eras Land - người đã có hơn 20 năm dẫn dắt và phát triển kinh doanh đối với lĩnh vực bất động sản, và đặc biệt là các chủ đầu tư uy tín, có quỹ đất sạch, quy mô lớn trên thị trường. Từ hành trình ấy, bà nhìn bất động sản không chỉ là tài sản hay cơ hội đầu tư, mà là không gian sống gắn bó lâu dài với con người và gia đình.Thật vậy, giá trị của một dự án bất động sản giờ đây không chỉ nằm ở vị trí hay tiềm năng lợi nhuận, mà ở cách dự án ấy phản ánh triết lý sống, phong cách sống, và xa hơn là tình yêu dành cho quê hương cùng tầm nhìn về một tương lai Việt Nam phát triển bền vững. Trong số 106 của podcast Vietnam Innovators, chúng ta sẽ cùng host Từ Ân, lắng nghe Bà Nguyễn Hương, chia sẻ những góc nhìn sâu sắc về những yếu tố quan trọng cần được ưu tiên hàng đầu và giá trị cốt lõi của bất động sản.____Đừng quên có thể xem bản video của podcast này tại: YouTubeVà đọc những bài viết thú vị tại: https://vietcetera.com/vn/bo-suu-tap/vietnam-innovatorNếu có bất cứ góp ý, phản hồi hay mong muốn hợp tác, bạn có thể gửi email về địa chỉ hello@vni-digest.com

Paul Williamson discusses the Luis Perales trade, recent free agency deals like Ha-Seong Kim to Atlanta and Adolis Garcia to Philly. He then breaks down five pitchers that had ERAs that did not lineup with their metrics. He has three arms that outperformed their metrics  and two the under-performed them. Presented by FanDuel SUBSCRIBE, Rate and Review on Apple and Spotify! Follow us on Twitter: @EthosFantasyBB Follow us on Bluesky: @ethosfantasymlb Join our Fantasy Sports Discord Server: https://discord.gg/jSwGWSHqaV Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of The Cardiac Recovery Room, moderator Vicki Morton, Director of Clinical and Quality Outcomes at Providence Anesthesiology Associates in North Carolina, USA, spoke with Alexander Gregory, a cardiovascular anesthesiologist and assistant professor in the Department of Anesthesiology, Perioperative and Pain Medicine, and the Libin Cardiovascular Institute at the Cumming School of Medicine, University of Calgary, Canada, and Dr. V. Seenu Reddy, a cardiothoracic surgeon at HCA's TriStar Cardiovascular Surgery in Nashville, Tennesee, USA, about the 10 things they hate about Enhanced Recovery After Surgery (ERAS).   Chapters 00:00 Introduction  01:38 Overcomplication  05:29 Simple Barriers  08:54 Change Obstructionists  10:52 Status Quo  12:49 Messing with Protocol  14:21 Giving Up on Protocol  16:48 Need for Patient-Reported Outcomes  19:18 Struggle Into Cardiac Subspecialty  21:30 Takeaways  The goal of this discussion was to identify specific challenges and propose potential solutions. They emphasize the importance of having two leaders—a champion and a co-champion—to effectively guide ERAS initiatives. Additionally, they discuss creating standing orders and issues related to microbarriers and resistance to change. They also highlight the need for customization of protocols, acknowledging the differences between surgeons who utilize ERAS and those who do not, as well as the tendency to maintain the status quo. Patient perspectives are another key focus, with a call to implement changes that enhance tracking and monitoring of patient outcomes. Furthermore, they explore the role of technology designed for patients, as well as applying ERAS principles to surgeries that fall “outside of the box.”   The Cardiac Recovery Room is the place to hear the conversations colleagues are having after the meetings. Each month, a new episode will be released featuring a leadership panel from the ERAS Cardiac Society.  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Support our sponsor this week by using the link below for the exclusive Solomonster offer!FACTOR MEALS ▶ Use code "solomonster50off" at http://www.factormeals.com/solomonster50off to get 50 PERCENT OFF your first box plus FREE BREAKFAST for one year!Solomonster reviews WWE Raw coming off of John Cena's retirement, with Gunther being booed out of the building, Austin Theory revealed as the masked man, CM Punk drops a bomb on Bron Breakker and not much else to speak of on an otherwise dull show.***Follow Solomonster on X (formerly Twitter) for news and opinion:http://x.com/solomonsterSubscribe to the Solomonster Sounds Off on YouTube:https://www.youtube.com/user/TheSolomonster?sub_confirmation=1Become a Solomonster Sounds Off Channel Member:https://www.youtube.com/channel/UC9jcg7mk93fGNqWPMfl_Aig/join

It's Taylor Swift's birthday, and somehow she's the one giving us gifts. In this episode of 13: A Taylor Swift Fan Podcast, we dive headfirst into the first two episodes of Taylor's Eras Tour documentary and her revealing, hilarious, and emotionally loaded appearance on The Late Show with Stephen Colbert. We unpack everything: the overwhelming emotion behind the Eras Tour, the responsibility Taylor carries as a global icon, the heartbreak and resilience surrounding Vienna, and the quiet moments that show who she really is when the spotlight dims. From backstage tears to bonus-day generosity, from Mirrorball validation to the power of audiobooks as emotional armor — nothing is off limits. Plus, we talk reputation rumors, surprise lyric changes, Swiftie clownery, Travis Kelce crumbs, dancer spotlights, and why Taylor's confidence still makes people uncomfortable (and why it absolutely shouldn't). This episode is joyful, heavy, validating, chaotic, and deeply human — just like Taylor herself.Happy birthday, Taylor. Thanks for once again reminding us why we picked the right one.  Stay Connected with 13: A Taylor Swift Fan Podcast Join the conversation in our exclusive  Lobster Lounge:  station.page/13  Contact the Podcast  Voicemail: (689) 214-1313  Email: the13podcast@gmail.com  Instagram: @the13podcast  TikTok: @the13podcast  Twitter/X: @the13TSpodcast  YouTube: 13: A Taylor Swift Fan Podcast  Follow the Hosts  Ana – @anaszabo13  Lacey – @laceygee13  Amy – @amysnichols  Nick – @heynickadams Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a message! On episode 326, because we had a lot of feedback on the 5 Eras of Maiden last week, we decided to go through the feedback We had a lot of fun with your lists, this episode reaches all of the emotions! Support the show

Danny is here with a bonus episode grab bag of Bravo news and views + a full recap of this week's episode of The Real Housewives of Potomac, which featured a potential eviction, multiple cowboy themes, and more! ORDER DANNY'S BOOK: https://linktr.ee/jolliestbunchDANNY'S (OTHER) BOOK: Smarturl.it/unrememberTwitter: @DannyPellegrinoInstagram: @DannyPellegrinoYouTube: www.YouTube.com/DannyPellegrino1TikTok: @DannyPellegrinoPatreon: www.Patreon.com/EverythingIconic Hosted on Acast. See acast.com/privacy for more information.

Today we’re going inside the world behind the Eras tour that stopped the world - with a deep dive into the first two episodes of Taylor Swift’s new docuseries End of an Era.Laura is joined by two MEGA Swifties on the mic as they break down the behind-the-scenes chaos: life on the road, how the show was built, how Taylor winds down after each stadium performance, and the work that really went into making the two-year phenomenon such a cultural beast.We’re also diving into what the series reveals about Taylor’s inner circle — from rare glimpses of her relationship with Travis Kelce to her “cosy friend” Florence Welch, plus the bond with her dancers and crew (including those headline-making bonuses) and the journey from “can’t dance” to commanding the stage night after night.LISTEN NEXTA Brutally Honest Review Of Wicked: For GoodA Brutally Honest Review Of Taylor Swift's New MovieA Brutally Honest Review Of Meghan Markle’s Christmas SpecialA Brutally Honest Review Of Nobody Wants This Season 2A Brutally Honest Review Of The Spice GirlsTHE END BITSOur podcast Watch Party is out now, listen on Apple or Spotify. Support independent women's media Follow us on TikTok, Instagram and Facebook. And subscribe to our Youtube channel. Read all the latest entertainment news on Mamamia... here. Discover more Mamamia Podcasts here. Do you have feedback or a topic you want us to discuss on The Spill? Send us a voice message, or send us an email thespill@mamamia.com.au and we'll come back to you ASAP! CREDITS Hosts: Laura Brodnik, Tina Burke and Bree Player Executive Producer: Monisha IswaranAudio Producer: Scott StronachBecome a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

It's not the way we're used to seeing a college football coach who helped his team win a championship, but this is Michigan's former head coach today, sitting in a small cinderblock, holding cell facing charges of home invasion and stalking. And a holiday shopping warning. Millions use Facebook Market Place to safely buy and sell gifts. But when one couple posted a laptop for sale, it led to a nightmare. The guys who showed up to their home to buy it attacked them with bear spray. Plus, you may have noticed Christmas decorations are bigger than ever this year, with inflatable Santas, snowmen, and grinches towering over homes. But if you want one for your yard, you may have some trouble tracking one down.  Alison Hall tells us why. And it's a big day for Swifties. Taylor Swift just released her new Disney Plus series about her Eras tour. She gets emotional talking about canceling shows because of a terror threat.   To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

We talk about how music enhances our sobriety and what our playlists look like. We also talk about sober concerts we've loved. Live shows are a revelation, not just because we remember everything, but because we are present in the moment. To Anna, listening to Taylor Swift is the closest she's come to feeling high (watching The Eras tour movie made her understand why people do ayahuasca). Lisa talks about the Rolling Stones and Grateful Dead shows.   For all you Swifties, dig into Swift Steps.  Check out all things Lisa and all things Anna. 

 Three Big Conversations: TikTok's most-used sound in 2025 was a 63-year-old love song - 8:40  Netflix and Paramount are in a bidding war for Warner Bros. - 22:38 Hollywood might be having a "God moment." - 35:52 Song of the Week: "Santa Tell Me" - by Ariana Grande - 1:02 Click here for the lyrics. In Other News: - 52:20 Taylor Swift will officially conclude her Eras era today, releasing a six-episode docuseries about her record-setting tour as well as "Taylor Swift | The Eras Tour | The Final Show," both streaming on Disney+. The Roman Catholic Archdiocese of New York took several big steps toward resolving 1,300 sex abuse claims against clergy. Australia's blanket ban of social media for all users under 16 took effect on Wednesday. Pop-folk artist Noah Kahan is dropping hints about his next album, and considering the popularity of his 2022 release Stick Season, it could be one of the biggest releases of 2026. Pantone named "Cloud Dancer"—a shade of natural white—as its color for 2026, stating that the shade represents "a calming influence in a frenetic society." Double your impact with End of Year Giving! Every dollar you give will be mathched dollar for dollar until the end of 2025! Get your question on Ask Axis! Send in your questions to ask@axis.org. For more Axis resources, go to axis.org.

TikTok's most-used sound in 2025 was a 63-year-old love song, Netflix and Paramount are in a bidding war for Warner Bros., and Hollywood might be having a "God moment."  Song of the Week: "Santa Tell Me" - by Ariana Grande Click here for the lyrics. In Other News: Taylor Swift will officially conclude her Eras era today, releasing a six-episode docuseries about her record-setting tour as well as "Taylor Swift | The Eras Tour | The Final Show," both streaming on Disney+. The Roman Catholic Archdiocese of New York took several big steps toward resolving 1,300 sex abuse claims against clergy. Australia's blanket ban of social media for all users under 16 took effect on Wednesday. Pop-folk artist Noah Kahan is dropping hints about his next album, and considering the popularity of his 2022 release Stick Season, it could be one of the biggest releases of 2026. Pantone named "Cloud Dancer"—a shade of natural white—as its color for 2026, stating that the shade represents "a calming influence in a frenetic society." Double your impact with End of Year Giving! Every dollar you give will be mathched dollar for dollar until the end of 2025! Get your question on Ask Axis! Send in your questions to ask@axis.org. For more Axis resources, go to axis.org.  

www.ladivademexico.com

www.ladivademexico.com

President Trump is offending his own voters when he mocks America's affordability crisis, Mark Zuckerberg is defunding the metaverse after losing $70B on the effort, and Secretary of State Marco Rubio is waging war on the use of “woke” fonts at the State Department. 14-time GRAMMY-winner Taylor Swift joins Stephen Colbert for a four-part conversation that begins with a look at her extraordinary globe-trotting “Eras” tour and the effect it had on her fans. Watch “The End of an Era” and “Taylor Swift | The Eras Tour | The Final Show” premiering Friday on Disney+.  To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

How does China's economic model work? Political economist Ben Norton explains the ideas behind Socialism with Chinese Characteristics, discussing China's socialist market economy, historical development, reform process, poverty reduction, industrial policy, and more. VIDEO with charts here: https://www.youtube.com/watch?v=6E89qUXTX-k Topics 0:00 Introduction 1:07 China has world's largest economy 3:01 China's economic development 3:54 Poverty reduction 6:56 Rising incomes 7:42 Life expectancy 8:57 Mortality rates 9:34 Reform and Opening Up 10:16 To get rich is glorious? 11:35 Deng Xiaoping's ideology 13:54 Primary stage of socialism 14:28 Chinese capitalists 15:54 Industrialization & urbanization 16:55 Birdcage economy (Chen Yun) 18:17 State ownership 19:40 State-owned enterprises (SOEs) 20:49 Grasp the large, let go of the small 22:22 Public property 23:16 SOE assets 24:14 Provincial & local governments 25:51 Golden shares in tech companies 26:54 Huawei, biggest worker-owned company 27:17 Rural cooperatives 29:09 Democracy in China? 31:40 Foreign investment in China 33:49 Global value chain 34:34 Foreign direct investment (FDI) 35:48 Industrial policy evolution 38:22 New quality productive forces 39:23 China's green energy revolution 40:24 World's manufacturing superpower 41:04 US deindustrialization & financialization 43:22 US bubble economy 44:37 China popped real estate bubble 46:50 Inequality & uneven development 48:31 Eras of the PRC 49:01 Common prosperity in New Era 49:34 Gini coefficient 50:26 Labor income vs capital income 51:48 Poverty alleviation 52:17 Wages of Chinese workers 52:44 Labor unions in China 55:19 USA funds anti-China labor groups 57:02 Marco Rubio takes over NED 57:32 Delivery workers 58:30 996 system is banned 59:23 Working hours in China 1:00:25 Imperialism & division of labor 1:03:51 AI & new cold war 1:04:45 Silicon Valley model: monopoly 1:05:43 Market competition in China 1:07:44 China opposes private monopolies 1:08:10 State planning 1:09:05 Cold War Two

Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article "End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer," focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to properly design novel trials investigating non-operative management while including the incorporation of biomarkers and patient perspectives in clinical trials. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today we are joined by JCO authors Andrea Necchi, Associate Professor of Medical Oncology at University San Raffaele and Medical Oncology at Ospedale San Raffaele in Milan, Italy, and Ashish Kamat, Professor of Urologic Oncology and Cancer Research at University of Texas MD Anderson Cancer Center. Both Professor Necchi and Professor Kamat are internationally recognized experts in the field of genitourinary malignancy and particularly in bladder cancer. Today we will be discussing the article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." So thank you for speaking with us, Professor Necchi and Professor Kamat. Dr. Andrea Necchi: Thank you, Davide, and thank you JCO for the opportunity. Dr. Ashish Kamat: Yeah, absolutely. It is a great honor and privilege to be discussing this very important article with you. So thank you for the invitation. Dr. Davide Soldato: The article that you just published in JCO reports the results of a consensus meeting that was held among experts in the field of genitourinary malignancy and particularly for bladder cancer. So the objective was really to define endpoints for a novel generation of trials among patients diagnosed with muscle-invasive bladder cancer. So my first question would be: what is the change in clinical practice and in clinical evidence that we have right now that prompted the start of such consensus in 2025? Dr. Andrea Necchi: So, we are living so many changes in the treatment paradigm of patients with muscle-invasive bladder cancer. In general, patients diagnosed with bladder cancer or urothelial cancer today, thanks to the advent of immunotherapy or immunotherapy combinations, and today thanks to the advent of novel antibody-drug conjugates like enfortumab vedotin in combination with immunotherapy that are actually changing the landscape of treatment of patients with metastatic disease and also are entering quite fast into the treatment paradigm of patients with organ-confined disease with a lot of clinical trials testing these combination therapies, neoadjuvantly or adjuvantly, before or after radical cystectomy. Having said that, by potentiating the efficacy of systemic therapy, an increasing number of patients that receive neoadjuvant therapy of any kind, at a certain point in time, result to have achieved a deep response to systemic therapy, evaluated radiologically with conventional imaging, CT scan or MRI, or with cystoscopy or with other urology-based techniques, urinary cytology, and so. And based on the fact that they achieve a complete response, so no residual viable disease after systemic therapy, they raise concern about the fact that they have to undergo surgery like radical cystectomy that is quite impactful for their quality of life and for the future of their lives after the surgery. So the point that the patients are raising, and the patients are raising this point, is primarily due to the efficacy of systemic therapy. And we have seen so many cases fortunately achieving a deep response. So the question about what to do with the patient that at a certain point, at the start with the commitment to radical cystectomy, but at a certain point in time change their mind towards something else if possible, depending on the fact that they have achieved a deep response, is something that is a question and is a need to which we have to provide data, information, and guidance in general to the patients. Dr. Davide Soldato: If we look at the population that the recommendations were formulated for, we are mainly speaking about patients who would be fit for cystectomy, and this is a very distinct population compared to those who are not fit for cystectomy, both from a medical oncology point of view but also from a urologic point of view in terms of surgery. So, can you explain a little bit to our listeners why you think that this distinction is critical and why you developed this recommendation especially for this population? Dr. Ashish Kamat: That is a very important distinction that you made. To build upon what Professor Necchi mentioned earlier, this question that we get from patients after neoadjuvant therapy or systemic therapy is not a new question. It has been something that they have been asking us for the last 20 or 30 years. "Do I really need to have my bladder taken out?" And patients who are especially not fit for surgery will sometimes say, "Do I need to have my bladder taken out? And if I cannot have my bladder taken out, am I going to just not have anything done?" Because the eligibility for radical cystectomy is also a moving target. Over the years with improvement in surgical technique, improvement in perioperative therapy, ERAS protocols, et cetera, it is really unusual for us to deny a patient the opportunity to have major surgery unless clearly they have very significant comorbid conditions. So I think this endeavor is more broadly encompassing of the patient population than what was evident in previous years. And I really want to give a shout out to Professor Necchi because what we did was, as part of the International Bladder Cancer Group and Professor Necchi is an integral part of the scientific advisory board, we broached this topic broadly during one of our discussions. And of course, Andrea always does this, he picks on a topic and then he says, "Okay, we need to discuss this really in detail," put together a multinational, multicenter collaborative group, but the driving force was our patients. Because our patients are constantly asking, "Do I need to lose my organ? Do I need to have radiation therapy?" which again, also, has a lot of side effects. So this was really to answer the question in today's day and age as to do we need to do local consolidation, and if so, in what way? It is not a new question, but we have newer therapies, newer technology, and better ways to answer this. So it is a much needed question that needs to be answered. And I think the distinction between non-surgical candidates and surgical candidates is a little bit blurred in today's day and age. Dr. Davide Soldato: What about the eligibility, for example, for cisplatin-based chemotherapy? Because I think that that is a very fundamental part of this type of strategy that we apply to patients with muscle-invasive bladder cancer. So we know that there are some caveats for proposing such treatment. And also this population was specifically defined inside this recommendation. Dr. Andrea Necchi: I think that the focus of our work is just to analyze what is happening after any type of systemic therapy the patient may get neoadjuvantly. So it is not actually a question of treatment eligibility or including cisplatin eligibility. This is an old question of today's practice and clinical trials. But regardless of what the patient received neoadjuvantly, the point that we have addressed in our consensus meeting was what to do next as a further step after systemic therapy or not. So basically we are- the consensus guidance includes all-comers, so patients to get any type of systemic therapy. So really non-selected based on specific features that determine a special eligibility to a special or a particular therapy. But an all-comer approach is always the winning approach for the translation to be in practice, an all-comer approach just focusing on what has happened after treatment and that we are assessing by the use of conventional imaging, MRI or CT, cystoscopy, urinary cytology, and trying to merge all together this information, all these features in a unique, shared, reliable definition of clinical complete response that could be used as a biomarker for the selection of newer therapies instead of pathological response that has been historically used, and maybe surrogate for the outcome, the long-term outcome and survival of these patients. Dr. Davide Soldato: A very specific point of the consensus was actually the definition of clinical complete response. As you were saying, this is actually a combination of several parameters including urinary cytology, the use of cross-sectional imaging, for example CT scan, but also the evaluation in cystoscopy of the bladder. Do you foresee any potential problems when applying this type of recommendation, not inside clinical trials, but in the context of routine clinical practice? Dr. Ashish Kamat: Absolutely. And that was the whole reason we had this consensus meeting. What happens nowadays in daily practice, and we see this every day at our center, we see patients referred to us. This definition or this sort of attempt to define clinical complete response is an ongoing issue. And urologists, medical oncologists, radiation oncologists are always looking to see, does my patient have a complete response? That definition and those paradigms have changed and evolved over the years. The FDA had a workshop many years ago looking at this very question. And it was to address the proposal that complete clinical response, which is a clinical definition, a clinical state, does this correlate with pathologic response? And with the technology and the systemic therapies we had then, the answer was 'no'. In fact, more patients got recurrent disease than did not get recurrent disease. And that is why, of course in the paper we mention the trials that looked at this question, the trials that evolved around this question. And I think the distinction between a clinical trial and daily practice is extremely important when we are looking at this definition per se. Because essentially what happens with this issue is that if the patient is not appropriately counseled, and if the physician does not do the appropriate clinical complete response assessment as Professor Necchi mentioned, right, cystoscopy, cytology, imaging, use of markers that are still in evolvement, we risk doing harm to the patient. So we caution in the paper too that this definition is not ready for prime time use. It is something that needs to be studied. It is a rigorous definition and currently we are recommending it for clinical trials. I am sure eventually it will trickle down into clinical practice, but that guidance was not the purpose of this consensus meeting. Dr. Davide Soldato: There are several parameters that are potentially evolving and could potentially enter inside of clinical practice. For example, you mentioned pelvic MRI and we have now very specific criteria, the VI-RADS criteria, we're able actually to diagnose and also to provide information. So along with these novel imaging techniques, we also know that there are novel biomarkers that could be explored, for example ctDNA and urinary DNA. So what I was wondering is, why were not these included inside the definition that you provide for clinical complete response? And do you think that, as we are designing these trials to potentially spare cystectomy for this patient, we should include these biomarkers very early so that we can actually provide better stratification for our patients and really propose this type of cystectomy-sparing strategy only to those where we are very confident that we have obtained a clinical complete response? Dr. Andrea Necchi: I would say you have just to wait. So a follow-up is ongoing and hard work is ongoing. At the time we met, at the time we established the meeting in mid-December last year, we had no information on the ctDNA data from major trials, with only a few exceptions. So we were just at the beginning of a story that was more than likely to change but still without numbers and without data from clinical trials. Now in just nine months or 10 months time, we have accumulated important data and newer data will be presented during just a few weeks and a few days regarding the ctDNA, circulating tumor DNA in particular, as a prognostic marker assessed baseline or assessed after neoadjuvant therapy. So the point is certainly well made and ctDNA is certainly well shaped to be incorporated in a future definition of clinical complete response. But you have to consider the fact that most of the data that we are accumulating related to ctDNA are about the post-cystectomy field or the metastatic field. So regarding neoadjuvant therapy, you know, we have neoadjuvant therapy in the context of bladder-sparing approach, basically we have no information. And the point that is emerging in our daily practice when using these biomarkers or in clinical trials, and the impression in general, is that it is a very strong biomarker associated with survival, but we absolutely do not know what is the performance of the test in the prediction of superficial bladder relapses, high-grade pTa relapse in the bladder that is left untouched in the patient. We are considering, and maybe it will be just a matter of further discussion, not just what is happening within the immediate endpoint of clinical CR, but also what is happening later with other survival endpoints. And for example, when looking at the type of events that we may see in this kind of bladder-sparing approaches, most of the events, also in the trials that have been published including the RETAIN study published in JCO, most of the events are related to superficial high-grade superficial non-muscle invasive relapses. So the ability to predict these types of events with ctDNA is completely unknown. Maybe, maybe other liquid biomarkers like urinary tumor DNA, utDNA, could be a bit better shaped in the prediction of this kind of events, you know. But we have still to build the story. So the question is good. The answer is yes, we will likely, more than likely incorporate liquid biomarkers in the definition, but we have to wait at least more data and more robust data in order to translate this information in routine practice, you know. Another consensus meeting is organized by IBCG and the same folks for November. This meeting will be primarily focused on the liquid biomarkers, the interpretation and use and approval and so of liquid biomarkers including bladder cancer. And we will likely be able to address all these, most of these open issues, so most of these points in the next meetings. Dr. Davide Soldato: In the consensus you say that probably clinical complete response is now ready to be included in early phase trials, so actually to test what is the efficacy of the regimens that is being evaluated inside of these trials. But you actually do very in-depth work of defining what are the most appropriate endpoints for later phase trials. So to be very specific, the phase three registrational trials that bring new regimens inside of this space. So I just wanted to hear a little bit about what was the definition for event-free survival, which you define as the most appropriate one for this type of trials. And as you were mentioning before, Professor Necchi, there is a very specific interest on the type of events that we observe, especially when we look at these superficial relapses inside of the bladder. So was this a very urgent matter of debate as we define which type of events should actually trigger event-free survival? And did you make a very thoughtful decision about why using this type of endpoint instead of others, for example metastasis-free survival? Dr. Ashish Kamat: Yeah, this was a matter of intense debate as you might imagine. And again, this is a moving target. So as Professor Necchi mentioned, we tend to partner with each other, our organizations, on having definitions of clinical complete response, biomarker, retreats, and then using that as a marker, and you might imagine this definition of what is appropriate event-free survival, what events matter to the patient, is something we have been talking about for two years. It was not just something that came up at the retreat. But at the retreat there was intense discussion. One of the things that we talked about was bladder-intact event-free survival because we are trying to spare the patient's bladder. And do we count bladder-intact event-free survival as something that is relevant? The patient advocates absolutely liked that, right? They wanted that. But then we also learned from some of the studies, for example from the RETAIN study, that the non-muscle invasive recurrences can actually lead to metastatic disease. It is not as benign when you have a patient with muscle-invasive bladder cancer that then develops a non-invasive tumor because maybe there is cancer growing underneath the surface that we don't detect when we look in the bladder. So a lot of those discussions were held, debated. It was a consensus. I have to say it was not 100% agreement on that particular definition, but it was broad consensus. And Andrea, do you want to clarify a little bit as to how we came about that consensus? Because I think this is a very important point we need to make. Dr. Andrea Necchi: We focused on a bit different definition of BI-EFS, Bladder-Intact Event-Free survival. Just stating EFS as an all-inclusive parameter including all type of high-grade relapse or progression or death that may happen to the patient. So that we were counting high-grade pTa, pT1, CIS relapses to the bladder and of course more deeper involvement in the muscle layer and so, and metastatic disease as a relapse. But the point is that as compared to the classical bladder-intact EFS definition of chemoradiation bladder-sparing approaches that is including muscle-invasive relapses only or death as events, we tried to be as inclusive as possible in order to be as much conservative as possible and to raise as higher the bar as possible for the success. And this is actually what the patients are asking us. So they are asking, "Okay, I can save my bladder, sparing radical cystectomy, but at which cost?" So in order to provide an answer, we have to be very, very cautious and be on the right shape, on the right position to say, "Okay, we have accomplished the most, the safest points, you know, by which you can proceed with the bladder-sparing." This is the first point. The other point is related to the MFS, metastasis-free survival that you have mentioned. For sure, it was recognized as a very important point for sure. But in the discussion was clear that our focus was in saving patients, curing the patient, and saving the bladder. Any single event, superficial event that may occur in the bladder-saving approaches of this kind may expose the patient to an extra risk of developing distant metastases, as it happened for example in the RETAIN study. So EFS defined as we have agreed and published, is actually a way of including or anticipating in a safest position the MFS. Because most or if not the entirety of the events of metastasis development in patients undergoing bladder-sparing after neoadjuvant systemic therapy were preceded by a superficial phase of disease relapse, you know. So I remember very, very few, or we can count just on the finger of one hand, the cases that have been reported in the literature developing de novo metastatic disease in the similar bladder-sparing approaches, in particular when using a maintenance immunotherapy strategy, you know, after they reach TURBT. So this is the reason why with all the limitation that Ashish has mentioned, with all the uncertainties that are still there, the nervousness that is still there, EFS, as defined in the protocol, as put in the paper, is to us at the moment is the safest way to use a primary endpoint in potentially registration trials of this kind with perioperative systemic therapy and response-adapted surgery. Dr. Ashish Kamat: And David, just to be absolutely clear for our listeners, right, so what was the event-free survival that we defined? Essentially it was a very inclusive definition. Event was defined as high-grade tumor persistence, recurrence, or progression during or after perioperative therapy, and receipt of any additional standard of care treatment including radical cystectomy, radiotherapy or even intravesical therapy. So this was done at the behest of our patient advocates because we really wanted to make a very robust definition that could be utilized appropriately as an adequate primary endpoint for both early and late phase bladder preservation trials. Dr. Davide Soldato: I think that it really highlights one of the points that I liked the most about this consensus is that it really incorporated the patient vision and a sort of shared decision making process when we are deciding how we want to design these trials that will explore this bladder-sparing surgery. And Professor Necchi mentioned something that I think will be also a very interesting question for trials that will be developed considering the activity of this combination that we are seeing right now, which is maintenance. Because right now our approach in the few cases where patients do not do any type of treatments after an induction with neoadjuvant treatments is basically represented by observation. So I was wondering if you think that the field will actually evolve to a sort of maintenance strategy even in patients that will achieve a complete clinical response? Dr. Andrea Necchi: We just mentioned briefly in the paper, this is a very important point that was touched during the discussion, and in particular was raised and discussed by FDA people participating in the meeting. And when looking at the data from the trials that were available and are still available thus far, we could provide a suggestion that maintenance immune therapy is the preferred approach in this kind of approach as it currently stands, as the data currently stand. Because the cleanest data towards the successful part of this journey is related to the studies that provided a kind of maintenance therapy, like the study with nivolumab or the RETAIN-2 study with maintenance immune therapy instead of RETAIN study that was just stopping treatment until surgery with MVAC chemotherapy. So in general the impression is that maintenance therapy may help in reducing the type of events, including the events that we incorporate in the EFS definition that we mentioned in the paper. The point that you mentioned is very important because on the other side we have a problem, a big problem of affordability and cost of the treatment. The de-escalation trials are an urgent need and represent a call for the studies. Unfortunately, as you mentioned, this is something that moves beyond the possibilities of this type of consensus because we don't have data and we have to accumulate data from clinical trials prior to saying, "Okay, certain patients could de-escalate therapy and stop therapy and some other not." So we are still at the very beginning. So we can do- we can discuss about this in the radical cystectomy paradigm but not in the bladder-sparing paradigm, you know. But this is for sure a point, a discussion point that will be taken, pretty well taken in one year or two year projection. Dr. Davide Soldato: I was wondering if in the consensus, considering that patient advocates and patient associations were also involved, did you decide to actually suggest the inclusion of patient-reported outcomes or the evaluation of shared decision-making in the development of this trial really as endpoints that should matter as much or as much as possible as event-free survival and clinical complete response? Dr. Ashish Kamat: Oh yeah, absolutely. We had patient advocates, we had the World Bladder Cancer Patient Coalition, Bladder Cancer Advocacy Network, patient representatives. And we always consider this. Shared decision-making is actually the impetus behind why these efforts have been launched, right? So it is the shared decision-making that is very, very important. It is the driving force behind what we do. And it is worth noting, for example, for the design of such studies, regulatory agencies consider response-based endpoints or overall survival as primary endpoints. But the patient advocates consider quality of life to be just as important, if not more important sometimes than overall survival numbers. Because patient advocates will say, "Well if I live longer but I'm miserable living longer, yes that works for regulatory agencies but doesn't work for us." So PROs clearly are very, very important. And, in fact, we just literally had a meeting in Houston, the IBCG meeting where PROs were a main point of what we discussed. So incorporating PROs in everything we do, not just this but everything we do, Dr. Necchi, myself, everybody involved in these fields realizes it is very, very important. So absolutely. Dr. Davide Soldato: I want to thank again Professor Necchi and Professor Kamat for joining us today. Dr. Andrea Necchi: Thank you. Dr. Ashish Kamat: It is our pleasure. Dr. Davide Soldato: Thanks again and we appreciate you sharing more on your JCO article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

The Eras tour has been an endless source of entertainment, excitement and speculation for the last four years. Now it is finally coming to a close, the last piece of the puzzle is The End of an Era Documentary and The Final Show which we hope will include lots of unrevealed secrets that give us a different perspective when it comes to how the tour was organized, carried out and came to a close.

Coach Ted talks about finding an internal purpose in your training and how training groups are cyclical. (Originally aired 10-16-2024)

Send us a message! On episode 326, we discuss the eras of Iron Maiden, all 5... of them! What? You think there are not 5? Well listen to our logic and see how you agree or disagree. Make a queet twote and tell us how many you think there are, and why, and which is your personal favorite at this time! If you aren't on Twitter/X, send an email to IronMaidenPodcast@gmail.com, or post in the facebook group and tell us what you think! Support the show

The discussion delves into the complex historical eras of Iraq, challenging binary understandings of its past and present. A professor at Haverford College and author of "Political Undesirables: Citizen Denaturalization and Reclamation in Iraq and Return to Ruin: Iraqi Narratives of Exile and Nostalgia", Zainab Saleh discusses how the Iraq she grew up in—during the Ba'ath Party reign and under Saddam Hussein—was a time of fear and repression, despite the earlier period of high hopes and political aspirations in the 1940s and 1950s. She explores the concept of nostalgia for the Saddam era, which exists even among those who suffered under the regime, because of the basic services that were provided. The conversation offers a nuanced timeline of modern Iraqi history, from World War I's role in creating Middle Eastern nation-states through the Ottoman and British rules, the monarchy, and the Ba'ath Party. A key focus is placed on the 1990s as a major turning point, with the 1991 bombardment and subsequent sanctions leading to the rapid deterioration of infrastructure, increased social problems like begging and corruption, and environmental collapse. We consider the argument that the Iran-Iraq War, the Gulf War, and the US invasion should be viewed as one long, continuous war. Saleh critiques the simplistic narrative that Americans brought to Iraq after 2003, arguing that it institutionalized a sectarian political system. She emphasizes that the American discourse—classifying Sunnis as loyalists and Shia or Kurds as oppressed—ignored the reality of mixed communities and complex political loyalties. Saleh explores the historical use of denaturalization in Iraq, a topic central to her latest book. She details how the British and subsequent Iraqi regimes used the pretext of "political undesirables" to strip citizens of their rights, citing examples such as Iraqi Jews in the 1950s and Iraqis of Iranian origin in the 1980s. 0:00 Introduction 1:50 When Did The Iraq You Grew Up In Start?2:54 The High Hopes of the 1940s and 1950s3:33 Nostalgia, Time, and Loss7:09 The Broad Phases of Iraqi History9:33 Cultural Renaissance Under the Monarchy10:00 Vibrant Leftist Politics in the Monarchy Era11:39 Nostalgia for the Monarchy13:00 The Largest Effect on Daily Life: 1991 Bombardment and Sanctions16:29 Connecting the Wars: One Long War17:59 The Lead-up to Saddam's Invasion of Kuwait19:33 The Vision of the Neoconservatives20:40 Misunderstandings about US Imperialism22:11 The Myth of Iraqi Sectarianism23:24 The Institutionalization of a Sectarian System25:27 The Role of the Iraqi Opposition Abroad28:29 Phases of Post-2003 Iraq29:12 The Civil War and Proxy War (2006-2008)30:20 Displacement and the Reorganization of Iraqi Society30:52 Social Mobilization: 2011 and the Tishreen Uprising (2019)31:24 The Catastrophe of ISIS34:29 The Problem with Nostalgic Photos40:14 When One Dictator Becomes a Source of Nostalgia41:16 The Book: Political Undesirables and Denaturalization41:59 The Deportation of Iraqis of Iranian Origin (1980)44:48 Denaturalization as a Systemic Pattern48:19 Issuing Passports After World War I51:00 The Expulsion of Iraqi Jews (1950)51:25 Iraqi Jews as an Integral Part of Society52:44 The Ancient History of Babylonian Jews55:20 The Basis for Expulsion58:19 Recommended Readings on Iraqi History Zainab Saleh is Assistant Professor of Anthropology at Haverford College and the author of books "Return to Ruin: Iraqi Narratives of Exile and Nostalgia" (2020) and "Political Undesirables: Citizenship, Denaturalization, and Reclamation in Iraq" (2025).Connect with Zainab Saleh

www.ladivademexico.com

Aughie and Nia discuss the Fuller Court, years 1888 - 1910. Melville Fuller was widely regarded as an adequate administrator but not a great intellectual. His court followed in the conservative steps of the Waite Court.

www.ladivademexico.com

Science editor Ian Sample sits down with co-host Madeleine Finlay and science correspondent Hannah Devlin to hear about three eye-catching stories from the week, including a study showing that the brain has five ‘eras', with adult mode not starting until our early 30s. Also on the agenda is new research showing the shingles vaccine not only protects against dementia but could actually slow its progress, and a paper exploring how ants sacrifice themselves when they become infected with pathogens to protect their healthy relatives. Help support our independent journalism at theguardian.com/sciencepod

In this episode, we're slicing into two of the most debated entries in the Halloween franchise: Halloween H20 and Halloween: Resurrection.We look back at what worked, what didn't, and everything in between as we revisit the late-'90s revival and its infamous early-2000s follow-up. We break down the characters, plot choices, kills, suspense, and behind-the-scenes drama that shaped each film.From unused scripts and abandoned concepts to potential unmade sequels, we explore the alternate paths these movies could have taken. And of course… we dive into the many versions of the iconic Myers mask that appeared across both films.Whether you love these entries, hate them, or fall somewhere in between, join us as we explore their legacy, their flaws, and their place in one of horror's most beloved franchises.If you enjoyed this - Check out my other content here - https://linktr.ee/FirstClassHorrorBecome a supporter of this podcast: https://www.spreaker.com/podcast/class-horror-cast--4295531/support.

Manuel Jabois reflexiona al hilo de la noticia que revela hay algunas hormigas obreras que, al infectarse con un hongo que podría propagarse por todo el hormiguero, provocan su propia muerte para evitar que se infecten sus compañeras. 

We're back this week for the first keeping up in a while now that Bricia is back from Oaxaca and there's so much to catch up on! Paulina is getting ready for quinceañera season, and we get into how different hosting and invitation etiquette can be between cultures. We also dive into Bricia's time in Oaxaca and what she learned for her next visit. We had so much fun learning and catching up today, and we hope you did too!    Super Mamás  IG: @_supermamas  Facebook: Super Mamás  Twitter: @_supermamas   Website: http://supermamas.com/    This is a Redd Rock Music Podcast  IG: @reddrockmusic  www.reddrockmusic.com  Learn more about your ad choices. Visit megaphone.fm/adchoices

See omnystudio.com/listener for privacy information.

As you age, your financial priorities will change with you, so it is often useful to segment your financial plan into decades, allowing your plan to evolve to meet the needs of the moment. Donna and Nathan discuss the typical areas of focus that come with each decade as you journey toward retirement. Also on MoneyTalk, Stock Trivia: Battle of the Sowas. Hosts: Donna Sowa Allard, CFP®, AIF® & Nathan Beauvais, CFP®, CIMA®, CPWA®; Air Date: 11/25/2025; Original Air Date: 2/7/2023. Have a question for the hosts? Leave a message on the MoneyTalk Hotline at (401) 587-SOWA and have your voice heard live on the air!See omnystudio.com/listener for privacy information.

Join me and special guest, Maia, as we embark on a high-seas adventure with Ironsworn: Sundered Isles. Maia's Game RoomInterested in leaving a rating and review, click here.Check out my Patreon or my ko-fi.Game: Ironsworn: Sundered Isles by Shawn TomkinIntro & Outro Music: Steve Morrison

This episode of The C.L. Brown Show features Louisville center Pete Nygra and Kentucky defensive back Ty Bryant to give their thoughts on Saturday's Governor's Cup rivalry showdown. Nygra, an Indianapolis native, tells why the Cards-Cats rivalry far surpasses the rivalry he grew up watching.

It's Taylor Swift Week 1! Sammi and Ashley are talking about the first TS Disney Plus documentary, "Folklore: The Long Pond Studio Sessions." Join the duo as they rave about Taylor's "bossness" and creativity during the pandemic, when she created the entire album and filmed this acoustic concert documentary. Plus, they discuss the cozy, folk-inspired, yet potentially "slasher movie" setting of the historic Long Pond studio, the big reveal of the mystery Folklore co-writer, William Bowery, and, of course, break down some of the music! Next week, it's time for a look at all the Eras!Produced by: Limitless Broadcasting Network.For more info, merch, and all the other podcasts, visit: www.limitlessbroadcastingnetwork.comCheck out Ashley's Disney deep dives at: pixiedustfiles.wordpress.comFollow your new Disney besties on Instagram @pixiedusttwinspodcastFollow Dan, honorary third host of the "Pixie Dust Twins" Podcast, and King of the Manifestos: @Dantaastic on Instagram and YouTube

Nia and Aughie discuss the Morrison Waite Court, years 1888 - 1910. The Waite Court had the opportunity several times to further civil rights, but did not; the Court found the Civil Rights Act of 1875 unconstitutional, and followed with similar judgments.

  Adam Harstad and Matt Waldman reprise their season-long RSP Film & Theory podcast with a discussion about redraft and dynasty concepts.  There are a lot of excellent writers and analysts in the fantasy industry. There are few that I hold in as high a regard as Adam (and not surprising he earned the FSWA's Fantasy Writer of the Year). He's a forthright human being with a tremendous intellect whose approach to analysis in this space differs from most. He's also an excellent fantasy GM in re-draft and dynasty formats.  Adam spends a lot of time examining results and dealing with broad themes of decision-making that help us become better fantasy players and fantasy analysts. https://youtu.be/QZzVXi6Ezac   Topics Value: Why the best team on paper is a good aiming point but not always the answer. Which players would we want to see in different NFL eras? Why the early 2000s might have been the greatest collection of running back talent. Now entering its 20th season, learn more about Matt Waldman's RSP  — the most in-depth analysis of offensive skill position players available (QB, RB, WR, and TE). Or if you already know the deal, go ahead and pre-order (you know you want to) at an even greater discount than the normal steal of a price.  Matt's new RSP Dynasty Rankings and Two-Year Projections Package is available for $24.95 If you're a fantasy GM interested in purchasing past publications for $9.95 each, the 2012-2024 RSPs also have a Post-Draft Add-on that's included at no additional charge.   Best yet, proceeds from sales are set aside for a year-end donation to Darkness to Light to combat the sexual abuse of children.  

Join host Hector Flores on this jam-packed episode of the Insert Name FC Podcast, brought to you by Belly Up Sports Media Network! Hector kicks things off with a heartfelt nod to both the 250th birthday of the U.S. Marine Corps and his personal journey as a Marine, before diving into family milestones and celebrations that shaped his week. This episode brings you wall-to-wall football coverage, spanning Liga MX playoffs, a full MLS Cup playoffs breakdown, and a thorough look at the US Men's National Team's international break call-ups. Hector shares his predictions, gripes about playoff formats, and excitement over young players who could shake up the North American soccer scene. Not just sticking to soccer, Hector squeezes in commentary on the Houston Texans' epic comeback and admits the pain of missing the game for a family Barcelona watch party. He also spotlights must-watch international matches, upcoming World Cup qualifiers, and picks for Players of the Week, all topped off with details about how fans can watch the action live. Whether you're MLS-obsessed, a die-hard El Tri supporter, or just looking for a passionate fan's take on all things footy (and a few family laughs), this episode is packed with news, predictions, shoutouts, and plenty of character. Don't miss it!

We've all heard it: "Nothing to eat or drink after midnight." But what if that long-standing rule isn't the best thing for our patients? In this week's episode of First Case, we sit down with Lisa Spruce, Senior Director of Evidence-Based Perioperative Practice at AORN, to challenge one of the most ingrained habits in surgical care. Together, we'll walk through the research behind Enhanced Recovery After Surgery (ERAS) protocols, evidence-based practices designed to optimize patients before, during, and after surgery. From preoperative nutrition to multimodal pain management and early mobility, ERAS is helping teams across the country reduce complications, shorten recovery times, and improve outcomes. Tune in to learn: ✅ Why strict NPO after midnight is outdated ✅ How ERAS protocols enhance safety and satisfaction ✅ Practical steps for implementing evidence-based change in your facility Tune in to learn and together we can move past an old idea and implement evidence-based practices! #operatingroom #onnurse #ERASprotocols #podcast #scrubtech #surgery #bestpractice

Aughie and Nia continue the SCOTUS Court eras discussion by talking about the Court of Chief Justice Salmon Portland Chase. The Chase Court era lasted from 1864 - 1873. Chase's Court tried to define the rights of formerly enslaved people as well as defining the immutability of the Union.

En un México rural, los rumores han comenzado a esparcirse como plaga. "Las brujas han vuelto" Se llevan a los niños, a los débiles, devoran cuerpos y dejan tras de sí un rastro de ceniza y muerte. Juana, una joven marcada por el destino, se verá arrastrada a una lucha contra las carroñeras, enfrentando el horror con fe, valor y desesperación. Pero algo más acecha en las sombras… algo las está guiando. Y cuando el cielo se tiñe de rojo y las bolas de fuego cruzan el firmamento, la comunidad se da cuenta de que el verdadero terror aún no ha llegado. Si quieres conocer esta historia y descubrir el destino de Juana y su pueblo. Hosted on Acast. See acast.com/privacy for more information.

MUSICRush fans lost their minds . . . in a good way . . . when they heard their favorite band was getting back together for some reunion shows. https://www.alternativenation.net/rush-reunion-ticket-prices-are-insulting/?utm_source=fark&utm_medium=website&utm_content=link&ICID=ref_fark Taylor Swift's "The Life of a Showgirl" sold a MASSIVE 4 million copies in its first week. That 4 million is in what they call "equivalent album units," which include both pure album sales and streaming activity. But most of that WAS in pure album sales: 3,479,500 copies. https://www.billboard.com/lists/taylor-swift-life-of-a-showgirl-number-one-billboard-200/largest-week-by-equivalent-album-units-earned/Taylor Swift announces behind-the-scenes Eras tour docuseries, plus new concert film. The End of an Era will air across six episodes on Disney+, with Swift promising ‘all the stories woven throughout' record-breaking tourThe Red Clay Strays had a flight they'll never forget. The band was on their way to the Redwest 2025 festival in Utah, when their private jet hit some severe turbulence. https://www.tiktok.com/@theredclaystrays/video/7560482862969916703 It's possible we might not have seen the last all-star concert under the name Back to the Beginning. The U.K. paper The Mirror reports that Monowise LTD, the company that's been overseeing the rights of the late Ozzy Osbourne for a while, has filed a trademark application in the U.S. for the Back to the Beginning name to be used for “entertainment services in the nature of live musical performance.” https://www.mirror.co.uk/3am/celebrity-news/ozzy-osbourne-final-gig-back-36061530After 40 years, keyboardist Jonathan Cain is leaving Journey. Guitarist Neal Schon broke the news first on social media, writing, "Jonathan Cain announced his farewell to Journey tonight… I'm nowhere near done!” https://societyofrock.com/jonathan-cain-confirms-exit-from-journey-after-years-of-tension/ Congratulations to Oasis singer Liam Gallagher, who just became a grandfather. The 53-year-old's daughter Molly announced over the weekend that she'd given birth to her son Rudy. https://www.instagram.com/p/DPrNZIqDI4m/Weezer's "Island in the Sun" is the band's first song in Spotify's Billions Club, which marks over one-billion streams on the platform.Gene Simmons was at The Secret Garden in Las Vegas Sunday to officiate the wedding of Anthrax and Pantera drummer Charlie Benante and his longtime girlfriend, former Butcher Babies and current Violent Hour singer Carla Harvey. https://www.facebook.com/watch/?v=2024830168054221 TVApple has announced that Apple TV+ is being renamed "Apple TV." https://9to5mac.com/2025/10/13/apple-tv-rebranded-as-just-apple-tv/ MOVING ON INTO MOVIE NEWS: Alec Bladwin and his brother Stephen were involved in a car crash in the Hamptons, New York, on Monday. https://pagesix.com/2025/10/13/celebrity-news/alec-baldwin-crashes-range-rover-into-a-tree-in-the-hamptons/ Jennifer Aniston says she turned down a casting offer from “Saturday Night Live” before “Friends” for one reason. https://www.thewrap.com/why-jennifer-aniston-declined-snl-casting-offer-lorne-michaels/PETA gave the movie "Good Boy" an award, because the filmmakers made sure its dog star was safe and comfortable. AND FINALLYLoudwire put together a list of the best Prog Rock Drummers – I have a top 7 - https://loudwire.com/best-prog-rock-drummers/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.